title: Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.
abstract: BACKGROUND
  Metabolic and cardiovascular health problems have become a major focus for clinical care and research in schizophrenia.
  
  
  OBJECTIVE
  To evaluate the content and quality of screening guidelines for cardiovascular risk in schizophrenia.
  
  
  METHODS
  Systematic review and quality assessment of guidelines/recommendations for cardiovascular risk in people with schizophrenia published between 2000 and 2010, using the Appraisal of Guidelines for Research and Evaluation (AGREE).
  
  
  RESULTS
  The AGREE domain scores varied between the 18 identified guidelines. Most guidelines scored best on the domains 'scope and purpose' and 'clarity of presentation'. The domain 'rigour of development' was problematic in most guidelines, and the domains 'stakeholder involvement' and 'editorial independence' scored the lowest. The following measurements were recommended (in order of frequency): fasting glucose, body mass index, fasting triglycerides, fasting cholesterol, waist, high-density lipoprotein/low-density lipoprotein, blood pressure and symptoms of diabetes. In terms of interventions, most guidelines recommended advice on physical activity, diet, psychoeducation of the patient, treatment of lipid abnormalities, treatment of diabetes, referral for advice and treatment, psychoeducation of the family and smoking cessation advice. Compared across all domains and content, four European guidelines could be recommended.
  
  
  CONCLUSIONS
  Four of the evaluated guidelines are of good quality and should guide clinicians' screening and monitoring practices. Future guideline development could be improved by increasing its rigour and assuring user and patient involvement.
authors.affiliation: University Psychiatric Centre, KU Leuven, campus Kortenberg Leuvensesteenweg 517, 3070 Kortenberg, Belgium. marc.de.hert@uc-kortenberg.be
authors.forename: M
authors.initials: M
authors.lastname: De Hert
authors.forename: D
authors.initials: D
authors.lastname: Vancampfort
authors.forename: C U
authors.initials: CU
authors.lastname: Correll
authors.forename: V
authors.initials: V
authors.lastname: Mercken
authors.forename: J
authors.initials: J
authors.lastname: Peuskens
authors.forename: K
authors.initials: K
authors.lastname: Sweers
authors.forename: R
authors.initials: R
authors.lastname: van Winkel
authors.forename: A J
authors.initials: AJ
authors.lastname: Mitchell
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D019317:Evidence-Based Medicine; D019983:Guideline Adherence; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D009765:Obesity / Q000453:epidemiology; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D014150:Antipsychotic Agents